Stryker Corporation (SYK) carries a ŷRobot AI score of 74 out of 100. The model's fair value estimate is $318.36, 14.2% above the last close of $278.77. The chart signal reads Bullish.
| Metric | SYK |
|---|---|
| AI score | 74 / 100 |
| Chart signal | Bullish |
| Fair value estimate | $318.36 |
| Upside to fair value | 14.2% |
| Previous close | $278.77 |
| P/E | 33.34 |
| Price / sales | 4.81 |
| Market cap | $105.60B |
| EPS | 9.92 |
| Revenue growth | 10.2% |
| 1-year price change | 7.1% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
As of Sep 30, 2026, ŷRobot's fair-value model estimates Stryker Corporation (SYK) at $318.36 against a last close of $278.77, implying 14.2% upside to the model's estimate.
The chart-signal model classifies SYK as Bullish as of Sep 30, 2026, with a signal score of 0.15 on a -1 to 1 scale.
SYK scores 74 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Sep 30, 2026.
SYK trades at 33.3 times earnings and 4.8 times sales as of Sep 30, 2026.
ŷRobot's seasonal forecast curve for SYK reads +1.3% at 30 days, +4.2% at 90 days, and +7.1% at one year as of Sep 30, 2026. Seasonal tendencies are historical patterns, not predictions.
Stryker Corporation's revenue growth is +10.2% and free-cash-flow growth is -1.1% on the latest reported figures.
SYK chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.